Apellis Pharmaceuticals' Stock Surges 27.70% This Week Following FDA Approval, Q2 2025 Financial Results, and Capped Royalty Purchase Agreements

Apellis Pharmaceuticals' stock price surged 27.70% this week due to FDA approvals for EMPAVELI, Q2 2025 financial results, and capped royalty purchase agreements. The company reported $178.5 million in total revenues, with SYFOVRE U.S. net product revenue reaching $150.6 million. Apellis Pharmaceuticals is a global biopharmaceutical enterprise advancing treatments for diseases through complement system modulation.